PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 137 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,068,156 | +19.8% | 30,827 | 0.0% | 0.00% | +33.3% |
| Q1 2024 | $891,825 | +324.9% | 30,827 | +236.8% | 0.00% | +200.0% |
| Q4 2023 | $209,901 | -18.9% | 9,154 | -2.3% | 0.00% | 0.0% |
| Q2 2023 | $258,689 | -75.3% | 9,366 | -79.4% | 0.00% | -80.0% |
| Q1 2023 | $1,045,879 | +24.5% | 45,473 | -40.9% | 0.01% | +25.0% |
| Q4 2022 | $839,961 | +29.4% | 76,990 | 0.0% | 0.00% | +33.3% |
| Q3 2022 | $649,000 | +15.7% | 76,990 | +8.5% | 0.00% | 0.0% |
| Q2 2022 | $561,000 | -54.3% | 70,930 | +49.7% | 0.00% | -50.0% |
| Q1 2021 | $1,227,000 | +26.8% | 47,387 | -1.3% | 0.01% | +50.0% |
| Q4 2020 | $968,000 | +6.0% | 48,007 | +2.8% | 0.00% | 0.0% |
| Q3 2020 | $913,000 | +10.7% | 46,707 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $825,000 | +300.5% | 46,707 | +60.4% | 0.00% | +300.0% |
| Q1 2020 | $206,000 | – | 29,117 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $84,864,191 | 21.18% |
| Cannon Global Investment Management, LLC | 69,900 | $2,422,035 | 11.28% |
| ADAR1 Capital Management, LLC | 1,603,932 | $55,576,244 | 10.49% |
| Checkpoint Capital L.P. | 355,000 | $12,300,750 | 7.42% |
| Fairmount Funds Management LLC | 931,890 | $32,289,989 | 3.65% |
| BVF INC/IL | 3,319,290 | $115,013,399 | 3.22% |
| RTW INVESTMENTS, LP | 5,286,404 | $183,173,899 | 2.84% |
| Kynam Capital Management, LP | 800,000 | $27,720,000 | 2.14% |
| 683 Capital Management, LLC | 604,449 | $20,944,158 | 1.58% |
| Birchview Capital, LP | 48,000 | $1,663,200 | 1.54% |